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Abstract: Objectives: The aim of this narrative review of the literature was to synthesize and 
comment the mechanisms of action of avocado/soybean unsaponifiable mixture (ASU-E, 
Piascledine®300) on articular tissues involved in the OA pathogenesis. Materials and methods: The 
search was performed in Pubmed and Scopus between January 1981 and December 2016. Keywords 
used were—any field—(Cartilage OR Bone OR Synovium) AND Avocado AND Soybean. 32 
articles out-off 35 found have been considered. The review has included eleven in vitro and animal 
studies investigating Avocado Soybean Unsaponifiables (ASU) from Laboratoires Expanscience 
(Piascledine®300) used separately or in combination. Only research articles published in English and 
French have been taken into account. Results: ASU-E stimulated proteoglycans synthesis in 
chondrocytes cultures and counteracted the effects of IL-1 on metalloproteases and inflammatory 
mediators. Some of these effects were associated with inhibition of NF-B nuclear translocation and 
stimulation of TGF-synthesis. ASU-E also positively modulated the altered phenotype of OA 
subchondral bone osteoblasts and reduced the production of collagenases by synovial cells. 
Conclusions: ASU-E has positive effects on the metabolic changes of synovium, subchondral bone 
and cartilage which are the main tissues involved in the pathophysiology of OA. These findings 
contribute to explain the beneficial effects of ASU-E in clinical trials.  
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1. Introduction 
Osteoarthritis (OA) is the most common form of arthritis affecting millions of people over the 
world and generating important costs for the social insurance. Recently, the OsteoArthritis Research 
Society International (OARSI) has defined OA as disorder involving movable joints characterized by 
cell stress and extracellular matrix degradation initiated by micro- and macro-injury that activates 
maladaptive repair responses including pro-inflammatory pathways of innate immunity. The disease 
manifests first as a molecular derangement (abnormal joint tissue metabolism) followed by anatomic, 
and/or physiologic derangements (characterized by cartilage degradation, bone remodeling, 
osteophyte formation, joint inflammation and loss of normal joint function), that can culminate in 
illness [1]. The main hallmarks of the disease are a progressive degradation of cartilage and meniscus, 
an inflammation of the synovial membrane and an abnormal subchondral bone remodeling leading to 
sclerosis. The most structural changes observed in cartilage are fibrillations, fissurations and at the 
late stage bone exposure. Chondrocytes form clusters and they undergo a hypertrophic differentiation 
associated with the mineralization of the extracellular matrix and angiogenesis [2]. OA synovial 
membrane displays a spectrum of changes including a marked hyperplasia of the lining layer, with a 
dense cellular infiltrate composed largely of lymphocytes and monocytes, through to a synovial 
membrane which is thickened by fibrotic tissue [3,4]. Overloaded subchondral bone is thickened as a 
result of an abnormal bone cells metabolism [5–7]. Further, microfractures and newly formed vessels 
constitute exchange routes between bone and cartilage [8]. Schematically, OA pathogenesis can be 
organised around three physiopathological vicious circles named « cartilage-cartilage »,  
« bone-cartilage » and « synovium-cartilage » loops (Figure 1). Abnormal mechanical strains 
induced cartilage lesions and subsequently chondrocytes activation. Activated chondrocytes release 
locally high levels of Reactive Oxygen/Nitrogen Species (ROS/RNOS), Matrix MetalloProteinases 
(MMP) (i.e. collagenases, aggrecanases) and cytokines (i.e. interleukin (IL)-1,-6,-8 and Tumor 
Necrosis Factor (TNF)). Among these cytokines, IL-1 plays a critical role by activating NF-B 
(Nuclear Factor kappa B) signaling pathway [9]. This cytokine, in association with others, stimulates, 
as an autocrine and paracrine manner, chondrocytes to produce more MMP and free radicals 
responsible for extracellular matrix degradation. This is the so called « cartilage-cartilage » vicious 
circle. Chondrocytes also communicate with subchondral bone cells via mediators like RANKL 
(Receptor Activator of Nuclear factor Kappa-B Ligand), a factor stimulating osteoclasts bone 
resorption [10]. Mechanical strains also stimulate osteoblasts to produce locally IL-6, but also growth 
factors like the Vascular Endothelial Growth Factor (VEGF) [11]. VEGF stimulates angiogenesis 
while IL-6, via channels and microcracks may stimulate overlying chondrocytes to produce matrix 
metalloproteinases [12]. By this way is created a vicious circle between subchondral bone and 
cartilage. The third pathogenic loop is between cartilage and synovial membrane. Osteochondral 
fragments, products of matrix degradation but also pro-inflammatory mediators (i.e. prostaglandin 
(PG) E2, nitric oxide (NO) or cytokines) trigger synovial membrane inflammation and activate 
synovial cells to produce catabolic and inflammatory mediators that directly degrade cartilage or 
stimulate chondrocytes to produce catabolic factors [13].  
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Figure 1. Representation of the OA physiopathology. MMP: matrix Metalloproteases; 
ADAMTS: A desintegrin and metalloproteinase with thrombospondin motifs;  
IL: Interleukin; PGE2: prostaglandin E2; RANKL: Receptor Activator of Nuclear factor 
Kappa-B Ligand; VEGF: Vascular Endothelial Growth Factor; NO: Nitric oxide.  
Therefore, physician and other health care providers need of efficient therapeutic modalities that 
target bone, cartilage and synovium cells. Further, recent advances in the understanding of the 
disease revealed an important interconnection between co-morbidities, like metabolic syndrome and 
cardiovascular diseases [14,15], and OA, indicating that OA management requires safe treatment 
with no deleterious impact on these co-morbidities. Pharmacological treatment is yet dominated by 
Non Steroidal Anti-Inflammatory (NSAIDS) drugs and acetaminophen despite their risk of severe 
adverse effects especially when administered in the long-term and mainly in elderly people with  
co-morbidities [16]. In addition, the efficacy of acetaminophen in osteoarthritis is highly  
challenged [16,17]. Beside these conventional treatment, there is a class of products called 
SYmptomatic Slow Acting Drugs in OsteoArthritis (SYSADOA). Avocado Soybean 
Unsaponifiables (ASU) mixture are members of this class. Currently, the only ASU mixture 
investigated in well-conduct Randomized Controlled Trials (RCT) is made up of unsaponifiables 
fractions one-third avocado oil and two-third soybean oil. This ASU mixture is commercialized as a 
drug in many countries and called Piascledine
®
300 (Laboratoires Expanscience, Courbevoie, France). 
In this paper, Piacledine
®
300 will be named ASU-E. At this time, they are four well-conducted RCT, 
all supported by the manufacturer, demonstrating a beneficial symptomatic effect of ASU-E in the 
treatment of hip or knee OA [18–21]. From Maheu et al. study [20], Piascledine®300 was 
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(LFI), from the first month of treatment and pain, as measured by global spontaneous pain, from the 
second month of treatment, versus placebo and over 6 months. In addition, the success rate of the 
treatment as defined by the rate of patients with an improvement of LFI ≥ 30% and a reduction in 
VAS pain ≥ 50%, was significantly higher in the Piascledine®300 versus placebo group at 6 months 
(p < 0.01). A meta-analysis including the randomized, double-blind, placebo-controlled trials 
concluded that patient may recommended to give Piascledine
®
300 a chance for 3 months as its 
effect size on pain was measured at 0.39 (95% CI: 0.01–0.76) and that on LFI was 0.45 (95% CI: 
0.21–0.70) [22]. In the Blotman study [21], indirect proof of symptomatic efficacy of 
Piascledine
®
300 was obtained as the intake of rescue NSAIDs was significantly decreased versus 
placebo group (p < 0.001). More recently, a large RCT including 399 patients with hip OA has 
demonstrated that 3-year treatment with ASU-E reduced the percentage of radiological progressors 
evaluated by measuring joint space width on radiograph, suggesting a structure-modifying effect in 
hip OA [23]. ASU-E is recommended by the European League Against Rheumatology (EULAR) for 
the management of knee and hip OA symptoms [24]. Recently, OARSI guidelines have qualified 
ASU-E as a treatment with an ―uncertain appropriateness‖ for knee OA management. According to 
the OARSI experts the term « uncertain » is not considered as a negative recommendation which 
could preclude the use of ASU-E. Rather, it requires a role for physician-patient interaction in 
determining whether such treatments may have merit in the context of their risk-benefit profile and 
the individual characteristics, co-morbidities and preference of the individual patient [25].  
One strategy to prevent or to treat osteoarthritis would consist in compound acting on the 
changes occurring in the three major tissues involved in OA pathogenesis: cartilage, synovial 
membrane and bone. Piascledine®300 (ASU-E) is a potential candidate for such an approach. This 
paper reviews the biological effects of ASU-E on these three tissues with the aim to explain how this 
product works in human (Table 1). 
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Table 1. Summary of the in vitro and animal studies evaluating ASU-E effects. 
Reference Product Dose and duration (ID) Model Results 
Chondrocytes in culture 
Mauviel A et al., 
1989 [31] 
ASU-E 1 or 10 g/ml 
ID: 24h or 5–7 days  
Primary rabbit articular 
chondrocytes in 
monolayer with or 
without IL-1 
Decreases PGE2 with or without IL-1 
Increases total collagens after 7 days of incubation 
No effect on cell proliferation 
Harmand MF, 
1990 [33] 
ASU-E 10 g/ml 
ID: 4h, 6, 9, 12 days 
Primary human normal 
or OA hip cartilage  
Increases GAG synthesis. 
Mauviel A, 
Loyau G, Pujol 
JP 1991 [32] 
ASU-E 10 g/ml 
ID: 48h 
Pre ID: 5 days prior IL-
1 48h 
Primary rabbit articular 
chondrocytes with or 
without IL-1 
Pre-incubation 5 days 
with ASU-E prior IL-1 
addition for 48h 
Totally blocks IL-1-stimulating effect on collagenolytic 
activity when incubated simultaneously with IL-1 
Partially counteracts IL-1- stimulating effect on 
collagenolytic activity when ASU-E was added 5 days 
before IL-1 







ASU-E 10 g/ml  
A-E: 3.3, 6.6, 10 g/ml 
S-E:3.3, 6.6, 10 g/ml 
ID: 72 h 
Human primary OA 
chondrocytes in 
monolayer with or 
without IL-1 
A-E and S-E inhibits spontaneous IL-8 and PGE2 
production 
A-E, but not S-E, inhibits spontaneous IL-6 production 
ASU-E inhibits IL-6, IL-8, PGE2 and MMP-3 spontaneous 
production. 
ASU-E is more effective than A-E or S-E added separately. 
ASU-E partially reverses IL-1 stimulating effect on IL-6, 
IL-8, PGE2 and MMP-3 production. 
Continued next page 
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Reference Product Dose and duration (ID) Model Results 
Boumediene K et 
al., 1999 [37] 
ASU-E  5, 10, 25 g/ml 
ID: 12–24 to 48h 
Primary calf articular 
chondrocytes in 
monolayer 
Stimulates the expression of TGF-1, TGF-2 and PAI. 
No effect on TGF-RI and RII. 





ASU-E: 0.625 to 40 
g/ml 
A-E:3.3 and 10 g/ml 
S-E: 6.6 and 10 g/ml 
ID: 3 to 12 days 
Human primary knee 
OA chondrocytes in 
alginate beads with or 
without IL-1 
3 days exposure to IL-1 
before treatment with 
ASU-E 
Increases AGG synthesis and accumulation in alginate 
beads. 
Partial recovery of AGG production after IL-1 treatment. 
Inhibits basal MMP-3, IL-6, IL-8, PGE2, MIP-1 production. 
Partially counteracts the IL-1-effect on MMP-3 and PGE2 
production. 
Gabay O et al., 
2008 [36] 
ASU-E 10 g/ml Mouse or human 
chondrocytes 
stimulated with IL-  
Cartilage submitted to a 
compressive 
mechanical stress (MS) 
Decrease of MMP-3 and -13 expression and PGE2 synthesis 
Inhibition of the degradation of IB and suppression of NF-
B translocation. 
Inhibition of Erk ½ but no effect on the other IL-1-induced 
MAPK. 
Osteoblasts in culture 
Andriamanalijaona 
et al., 2006 [48] 
ASU-E 10 g/ml 
ID 48h ASU-E + IL-1 or 
24h IL-1 followed by 24h 
ASU-E or 24h ASU-E 
followed IL-1 
Human alveolar bone 
explant or human 
alveolar bone cells in 
monolayer with or 
without IL-1. 
In basal condition, ASU-E had no effect on TGF-1 gene 
expression.  
Pre-treatment with ASU-E or ASU-E added with IL-1 
counteracts the inhibitory effect of IL-1 on TGF-1 gene 
expression. 
In basal condition, ASU-E stimulated protein synthesis. 
ASU-E added simultaneously with IL-1 counteracts the 
inhibitory effect of IL-1 on TGF-1 protein production. 
Continued next page 
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Reference Product Dose and duration (ID) Model Results 
Henrotin Y et al., 
2006 [45] 
ASU-E 10 g/ml 
ID: 72h 
Human osteoblasts coming 
from the sclerotic or non-
sclerotic subchondral bone 
of cadavers with idiopathic 
OA. 
Inhibits IL-1 by non-sclerotic osteoblasts, but has no effect 
on OC, AP, TGF-1 and IL-6. 
Decreases ALP, OC and TGF-1 synthesis by sclerotic 
osteoblasts, but has no effect on PTHrp, IL-6 and IL-1. 
Osteoblasts/chondrocytes co-culture 
Henrotin Y et al., 
2006 [45] 
 
ASU-E 10 g/ml 
ID: 72h 
Human OA chondrocytes 
co-cultured or not with 
osteoblasts (obtained from 
sclerotic (SC) or non-
sclerotic (NSC) zones of 
OA subchondral plate 
Prevention of the inhibitory effects of SC osteoblasts on 
matrix components by pre-treatment of SC osteoblasts with 
ASU-E. 
Increase of type II collagen mRNA level in co-culture with 
ASU-E pre-treated SC osteoblasts. 
No modification of MMP, TIMP-1, TGF-1, TGF-3 or iNOS 
gene expression and COX-2 mRNA levels in chondrocytes 
when co-cultured with ASU-E pre-treated SC osteoblasts. 
Synovial cells in culture 
Mauviel et al., 
1989 [31] 
ASU-E 0.1, 1 and 10 g/ml 
ID: 24h or 14 days 
Rheumatoid human 
synovial cells in 
monolayer with or without 
IL-1 
Partially reverses the inhibitory effect of IL-1 on collagen 
synthesis after 24 h. 
Slightly increases type I and type III collagen synthesis after 
14 days of incubation.  
Inhibits basal and IL-1 stimulated PGE2 production.  
Mauviel, Loyau, 
Pujol, 1991 [32] 
ASU-E 10 g/ml 
ID: 48h 
Pre ID: 5 days prior IL-1 
48h 
Rheumatoid human 
synovial cells in 
monolayer with or without 
IL-1 
Increases collagenolytic activity in basal condition. 
Partially blocks IL-1-stimulating effect on collagenolytic 
activity when incubated simultaneously with IL-1 
Totally counteracts IL-1- stimulating effect on collagenolytic 
activity when ASU is added 5 days before IL-1 
Continued next page 
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Reference Product Dose and duration (ID) Model Results 
Cinelli M et al., 
2009 [44]  
ASU-E 5, 10 and 20 g/ml 
ID: 48h 
Healthy or RA 
synoviocytes cultured in 
monolayer 
Decreases VEGF production and increase TIMP-1 by RA 
human synovioctyes. 
Animal studies 





ASU-E :39 mg/kg/day or 




ID: 2 weeks 
Control: saline/tween 80 
solution 
Femoral head cartilage of 
rat wrapped in piece of 
sterile cotton and 
implanted into 
subcutaneous tissue of 
mice  
ASU-E, A-E and S-E reduce the loss of GAG and 
hydroxyproline from cartilage induced by granulomatous 
tissue.  
The greatest effect is observed with ASU-E. 
ASU-E effect on GAG and hydroproline content is dose-
dependent. Treatment with ASU-E, A-E or S-E inhibits the 
formation of granulomatous tissue around the cartilage 
implant but the most market effect is exhibited by ASU-E.  
Cake M et al., 
2000 [43] 
 900mg/weekday 
Placebo: paraffin oil 
ID: 2 or 5 months 
Mature merino wheters 
with OA induced by 
bilateral lateral 
menisectomy 
N = 48 
Reduces loss of toluidine blue stain in tibial plateau than in 
placebo or non-operated controls. 
Increases uncalcified cartilage thickness in the middle zone 
of the lateral femoral condyle. 
Lower increase of subchondral bone plate thickness in the 
lateral tibial plateau.  
Altinel L et al., 
2007 [42] 
ASU-E 300 mg every day or 
every 3 days 
Control: normal diet 
ID: 3 months 
Male outbred sheepdogs 
N = 24 
Increase of both TGF-1 and TGF-2 levels in knee joint fluid 
in treatment groups compared to controls 
Continued next page 
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Reference Product Dose and duration (ID) Model Results 
Boileau C et al., 
2009 [40] 
ASU-E 10 mg/kg/day 
ID: 8 weeks 
Experimental knee dog 
model (anterior cruciate 
ligament transection) 
N = 16 
Decrease of the size of the macroscopic lesions (tibial 
plateaus) compared to control  
Decrease in the severity of cartilage lesions (tibial plateaus 
and femoral condyles) 
Decrease in the scores of all histological parameters 
(structural changes, cellularity, Safranin-O staining and 
pannus invasion on the femoral condyles) 
No difference on the tibial plateaus for Safranin-O and 
pannus invasion 
Reduction of iNOS and MMP-13 production in cartilage 
Reduction of the total histological changes and cellular 
infiltration in synovium 
Reduction of loss of subchondral bone volume and calcified 
cartilage thickness 
Jaberi F et al., 
2012 [41] 
ASU-E 300 mg every day 
Placebo: empty capsule 
ID: 3 months  
Male outbred dogs 
Full-thickness cartilage 
lesion in both femoral 
condyle 
Microfracture in the left 
knee 
N = 22 
No significant differences in cartilage surface histology, cell 
distribution, and cell viability. 
ASU-E: Avocado/Soybean Unsaponifiables from Expanscience; A-E: Avocado fraction from ASU-E; COX: cyclooxygenase; GAG: glycosaminoglycan; 
IL: interleukin; iNOS: inducible Nitric Oxide synthetase; MMP: Matrix Metalloproteinases; MAPK: Mitogen-activated protein kinases; MIP: 
Macrophage Inflammatory protein; NF: Nuclear factor; PAI: Plasminogen activator inhibitor; PGE2: prostaglandin E2; PTH-rp: Parathyroid hormone 
related peptide; RA: Rheumatoid arthritis; S-E: Soybean fraction from ASU-E, TGF: Transforming growth factor; TIMP: Tissue Inhibitor of 
Metalloproteinases; VEGF: Vascular Endothelial Growth Factor. 
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2. Materials & methods 
The search was performed in Pubmed and Scopus between January 1990 and November 2016. 
Keywords used were—any field—(Cartilage OR Bone OR Synovium) AND Avocado AND Soybean. 
32 articles out-off 35 found have been considered. The review has considered eleven in vitro and 
animal studies investigating the biological activity of the ASU-E (ASU produced by Laboratoires 
Expanscience, Courbevoie, France). Only research articles published in english have been taken  
into account.  
2.1. ASU-E definition 
Laboratoires Expanscience have developped and produced a pharmaceutical product, 
Piascledine
®300, which is effective for the ―symptomatic treatment of hip and knee osteoarthritis‖. 
The active principle of this pharmaceutical compound is called ASU Expanscience
TM
 (ASU-E) and is 
composed of a unique mixture of soybean unsaponifiables and avocado specific unsaponifiables [27]. 
Unsaponifiables are a set of molecules, soluble in plant oils that are not transformed in soaps during 
oil hydrolysis using strong bases. This chemical reaction being called saponification. The 
specificities of the process yielding the ASU-E are protected by patents (patent US 314 118, 1994, 
patent PCT FR00/02 601, 2000; Patent PCT FR02/02715, 2002). The originality of Piascledine
®
300 
is based on the A/S ratio (1 : 2) and its specific composition of both unsaponifiables, resulting from 
the proprietary process. The main fraction of avocado oil unsaponifiables (the H fraction), 
accounting for up to 50%, corresponds to a family of nine molecules out of which eight have been 
chemically characterized [28]. They are composed of a furyl nucleus, substituted in position 2 by an 
aliphatic, mono- or polyunsaturated chain. The chain length varies from 13 to 17 carbon atoms, 
always an odd number [29]. This fraction is highly specific for the avocado oil unsaponifiables 
contained in ASU-E and may be linked with its pharmacological activities. Squalen (2%), long-chain 
saturated hydrocarbons (up to 5%), polyols (up to 15%), tocopherols (trace amounts) and sterols 
(between 4 and 20%), mainly as -sitosterols, are the other components of the avocado 
unsaponifiables. The soybean oil unsaponifiables, almost totally identified, include saturated 
hydrocarbons (about 1%), squalen (about 4%), tocopherols (around 10%), sterols (between 40 and 
65%), terpene alcohols (about 1–10%), aliphatic alcohols (less than 1%) and methyl sterols (less than 
5%) [30]. In France, ASU-E is widely administered by oral route at a dose of 300 mg per day.  
2.2. ASU-E on cartilage metabolism 
2.2.1. In chondrocyte culture 
ASU-E was first tested on rabbit articular chondrocyte cultured in monolayer. After 24 hours 
exposure, ASU-E (0.1 to 10 g/ml) did not significantly modulate collagen synthesis. Conversely, 
long incubation periods (8 to 14 days) with ASU-E increased collagen synthesis [31]. Incubation of 
rabbit chondrocytes for 48 hours with 10 µg/ml of ASU-E slightly increased collagenase  
production [32]. This effect was no longer observed and remains unexplained. In in vitro 
experimentation, IL-1β was used to mimic the metabolic changes occurring in vivo in OA cartilage. 
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As expected, incubation of rabbit chondrocytes with IL-1β induced an important release of 
collagenase. ASU-E (10 µg/ml) totally abolishes its action. Moreover, incubation of rabbit 
chondrocytes for 5 days with ASU-E prior to a 48 h-exposure to IL-1 prevents partially the effect  
of IL-1. 
In human chondrocytes, ASU-E (10 g/ml) increased proteoglycans synthesis and accumulation 
in the extracellular matrix. This effect is significant after 6 days of incubation and is more marked in 
OA than normal chondrocytes [33]. In primary human OA chondrocytes, short-term (up to 72 hours) 
exposure of ASU-E (10 g/ml) inhibited spontaneous and IL-1-induced synthesis of stromelysin-1 
(MMP-3), IL-6, IL-8 and PGE2 [34]. Thereafter, to investigate the long-term effect of ASU-E (12 
days), human OA chondrocytes were cultured in three dimensional alginate beads [35]. In this 
tridimensional matrix, chondrocytes continue to express a cartilaginous phenotype for at least 12 
days and newly synthesized extracellular matrix accumulate around spherical chondrocytes 
entrapped in alginate scaffold. One major finding of this experience was that 12 days of ASU-E 
exposure did not affect cell viability, confirming the absence of toxicity of this product. Further, 
ASU-E increased in a dose-dependent manner aggrecan synthesis quantified by a specific sandwich 
enzyme-linked immunosorbent assay (ELISA) using two monoclonal antibodies, one raised against 
the keratan sulfate region of aggrecan and another directed against the hyaluronic acid binding region 
of the molecule. In parallel, ASU-E also inhibited the synthesis of pro-inflammatory mediators 
including Macrophage Inflammatory Protein (MIP)-1, Prostaglandin (PG)E2, Nitric Oxide (NO),  
IL-6, IL-8 and the production of MMP-3. In this experimentation, human chondrocytes were also 
pre-incubated with IL-1β for 3 days prior treatment with ASU-E. As anticipated, IL-1β pre-treatment 
inhibited aggrecan production. After 9 days of treatment with ASU-E, the production of aggrecan by 
chondrocytes was restored. In contrast, aggrecan production remained inhibited in chondrocytes 
culture untreated with ASU-E. This finding indicates that ASU-E may reverse the deleterious effect 
of IL-1β on the production of major cartilage matrix components. This study also demonstrated that 
ASU-E at the ratio A1S2 had a significantly more marked effect on IL-6, IL-8 and NO production 
than A or S added alone at the same concentration as in the A1S2 mixture. Together, these 
observations add support to the use of avocado/soybean mixture to treat OA.  
This was confirmed by Gabay et al. [36] on costal mouse chondrocytes cultured in monolayer 
and stimulated by IL-1β. ASU-E (10 g/ml) decreased IL-1β-stimulated MMP-3 and collagenase-3 
(MMP-13) gene expression and PGE2 production. In addition, this study identified the signaling 
pathways targeted by ASU-E. ASU-E inhibited Nuclear Factor (NF)-B nuclear translocation and the 
phosphorylation of Extracellular signals Regulated Kinases (ERK) 1/2 pathway but had no effect on 
p38 and Jun-amino-terminal Kinase (JNK) pathways. Similarly, ASU-E decreased ERK1/2 
phosphorylation induced by compression of mouse cartilage explants suggesting that ASU-E, not only 
counteracts the effects of chemical deleterious factors like IL-1, but also those of mechanical stress. 
The positive effects ASU-E on cartilage metabolism were explained by the increase of 
Transforming Growth Factor (TGF) β isoforms 1 and 2 production. Indeed, ASU-E at the 
concentrations of 10 and 25 g/ml increased the synthesis of both TGF isoforms by bovine 
chondrocytes in monolayer [37]. Interestingly, ASU-E appeared to synergize with TGF-1 to stimulate 
the expression of TGF-1, but not TGF-2 gene. These growth factors are well-known for their 
capacity to stimulate the synthesis of extracellular matrix components and counteracts IL-1 effects. 
Therefore, it was speculated that ASU-E increases TGF-1/2 which in turn stimulate aggrecan 
production and counteracts IL-1 stimulating effects on MMP and inflammatory factors production [37]. 
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ASU-E (10 and 25 g/ml ) also enhanced the synthesis of Plasminogen Activator Inhibitor (PAI)-1 
by bovine chondrocyte, an effect that participates in blocking the plasmin cascade that leads to 
metalloprotease activation. Given that TGF-1 itself is known as a stimulant of PAI-1 expression in 
most cell types, including articular chondrocytes [38], it may be possible that part of the increased 
PAI-1 expression observed here could be due to a primary effect of ASU-E on TGF-1 and TGF 2 
synthesis. This finding indicates that ASU-E, not only inhibits the synthesis of key MMPs involved 
in OA pathogenesis, but also regulates the activation process of these enzymes.  
2.2.2. In animal model 
The first study evaluating in vivo the possible ―chondroprotective‖ effect of ASU-E was 
performed using a model in which rat articular cartilage wrapped in cotton was implanted 
subcutaneously in mice. The presence of cotton induces a granulomatous reaction which enhances 
the destruction of adjacent cartilage. Agents that tend to delay or prevent cartilage degradation might 
be suggested to have a ―chondroprotective‖ action, which may or may not be linked to an associated 
anti-inflammatory effect on the granulomatous lesion itself [39]. In this model, unsaponifiables of 
avocado (13 mg/kg) and soybean (26 mg/kg) were tested individually or in combination at the ratio 
1 : 2 (39 mg/kg) as is found in ASU-E. The products were administrated orally during 2 weeks. 
Compared to saline solution, A or S unsaponifiables administrated individually or in combination 
partially prevented the loss of hydroxyproline and glycosaminoglycans in cartilage. The combination 
was significantly more efficient on these parameters than avocado and soybean added separately. As 
hypothesized, this effect may results of an anti-inflammatory effect of ASU-E on granulomatous 
tissue. Indeed, ASU-E decreased the size and fluid content of the granuloma mass surrounding the 
cartilage, indicating a potent anti-inflammatory effect.  
In dog, OA can be induced experimentally by the section of cruciate ligament. The section of 
ACL induced an instability responsible for abnormal strain at the cartilage surface, and consequently 
the degradation of this tissue. In this model, Boileau and colleagues [40] have compared the effects 
of ASU-E (10 mg/kg/day) vs placebo administrated orally during 8 weeks immediately after surgery 
on the cartilage and subchondral bone structural changes. By immunohistochemistry, they also 
investigated the effects of ASU-E on Nitric Oxide Synthetase (iNOS) and MMP-13 expression. 
iNOS synthesized high levels of NO in inflammatory condition and MMP-13 is a key MMP 
responsible for type II collagen degradation. Interestingly, ASU-E prevents the appearance of 
cartilage lesions. Histologically, the severity of cartilage lesion in both tibial plateaus and femoral 
condyles and the cellular infiltration in synovium was decreased. Treatment with ASU-E also 
reduced loss of subchondral bone volume and calcified cartilage thickness compared to placebo.  
Another group of researchers has investigated in 22 outbred male dogs the effects of ASU-E on 
the healing of full-thickness cartilage lesion in the medial femoral condyle associated or not with 
subchondral bone microfracture. Microfracture is one of the most commonly used primary surgical 
interventions to promote cartilage healing by inducing the production of fibrocartilage tissue and by 
increasing the amount of type II collagen in the cartilage tissue. Dogs received ASU-E 300 mg/day or 
an empty capsule as placebo during 12 weeks. In this model, there were any additive effect of ASU-E 
to microfracture induced repair tissue as evaluated by ICRS visual histological assessment scale [41]. 
In healthy dogs, 3 months of ASU-E (300 mg/day or 300 mg every three days) treatment increased the 
levels of TGF-1 and 2 in the knee synovial fluid when compared to the controls (normal diet) [42]. 
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As the sheep’s knee is the most similar to the human knee, an ovine model of OA is relevant to 
study drug efficacy. In sheep, lateral menisectomy induced gross pathological changes comparable 
with early human OA, with articular cartilage erosion in the lateral compartment and moderate 
market osteophytes. Histological lesions are limited to lateral compartment after 3 months, but 
extend to the entire joint after 6 months. Using this model, Cake et al. [43] has showed that ASU-E 
(900 mg/weekday) administrated orally during 6 months tended to decrease macroscopic and 
histological severity of OA lesion. However, this difference was not significant. In contrast, results 
obtained by computer-assisted histomorphometric analysis revealed subtle though statistically 
significant effects of the drug in maintaining articular cartilage proteoglycan content and decreasing 
subchondral bone sclerosis in lateral compartment [43]. 
2.3. ASU-E on Synovium inflammation  
Three studies investigated the effect of ASU-E on human rheumatoid synovial cells [31,32,44]. 
In these experiments, rheumatoid synovial cells were enzymatically removed from samples obtained 
during hip operations and cultured in monolayer. ASU-E (0.1 to 10 g/ml) did not affect the 
spontaneous production of collagens by synovial cells even after 14 days of incubation. As 
anticipated, IL-1 inhibited collagen synthesis by these cells. In the presence of IL-1, ASU-E  
(10 g/ml) restored collagen synthesis to levels similar to those of the control cultures. At a 
concentration of 10 µg/ml, ASU-E reduced the amount of PGE2 secreted by 77% relative to the 
control cultures and slightly inhibited the stimulatory effect of IL-1 (-20%). The unsaponifiables 
extracts therefore appear to work against the inhibitory effect exerted by IL-1 on collagen synthesis. 
The same group demonstrated that incubation of synovial cells for 48 h with 10 g/ml of ASU-E 
increased collagenase activity measured in the culture supernatant. IL-1 (100 pg/ml) induced an 
important increase of collagenase activity. This IL-1-stimulating effect was partially inhibited by 
ASU-E when it is added simultaneously for 48 hours. Moreover, incubation of synovial cells for 5 
days with ASU-E (10 g/ml) prior to a 48 h-exposure to IL-1 prevented the effect of IL-1. These 
results suggest that ASU-E could, at least partially, inhibit the harmful effects of IL-1 by reducing 
the collagenolytic activity of synovial cells. Finally, Cinelli et al. [44] compared the effect of ASU-E 
on the production of Vascular Endothelial Growth factor (VEGF) and Tissue Inhibitor of 
MetalloProteases (TIMP)-1 by rheumatoid or healthy synoviocytes. In RA synoviocytes, ASU-E 
significantly reduced VEGF levels, in a dose-dependent manner, while in healthy synoviocytes only 
ASU-E 10 and 20 g/ml , slightly but significantly, reduced VEGF levels with respect to the basal 
value. ASU-E induced a significant increase in TIMP-1 levels with respect to baseline values only in 
RA at 20 g/ml [44].  
2.4. ASU-E on subchondral bone remodeling 
OA subchondral bone osteoblasts expressed a particular phenotype that contributes to abnormal 
subchondral bone remodeling. In monolayer, OA osteoblasts coming from the thickening (called 
sclerotic) subchondral bone located just below the main cartilage lesion produced higher Alkaline 
Phosphatase activity (AP), VEGF, IL-6, IL-8, osteopontin (OPN), osteocalcin, TGF-β1 and type I 
collagen, but less ParaThyroid Hormone related peptide (PTHrp) than osteoblasts coming from the 
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non-thickening neighbouring area (called non-sclerotic, NSC) [7]. IL-1 production was similar in 
both cell type cultures.  
Aside from inhibition of IL-1ß production, ASU-E (10 µg/ml) had no effect on NSC osteoblasts. 
In contrast, ASU-E significantly decreased AP, OC, and TGF-ß1 synthesis by SC osteoblasts  
(p < 0.01), but had no effect on PTHrP, IL-1ß, or IL-6 production [45]. Interestingly, IL-6 with its 
soluble receptor (IL-6R) enhanced VEGF and MMP-13 production by both NSC and SC  
osteoblasts [46]. ASU-E (10 g/ml) drastically inhibited VEGF and MMP-13 production by both cell 
types treated with IL-6/IL-6R [46]. These effects of ASU-E on osteoblast could be related to the 
effects of this product on the synthesis of TGF-. Indeed, ASU-E counteracts the inhibitory effect of 
IL-1 on TGF-1 production by bone cells from alveolar maxillar bone, and synergized with IL-1 to 
stimulate TGF-2 protein production [48].  
2.5. ASU-E on Bone/cartilage crosstalk 
The bone-cartilage crosstalk can be investigated by co-culturing human osteoblasts and 
chondrocytes. In this model, osteoblasts of the sclerotic or non-sclerotic area of OA subchondral 
bone were cultured in monolayer and OA chondrocytes in alginate beads. Osteoblasts and 
chondrocytes were separated by a porous membrane allowing passage of soluble mediators.  
When they were co-cultured with sclerotic osteoblasts, chondrocytes produced significantly less 
aggrecan, whereas genes coding for MMP-3 and MMP-13 were upregulated [46]. The pretreatment 
of SC osteoblasts with ASU-E (10 g/ml) fully prevented the inhibitory effects of SC osteoblasts on 
aggrecan and type II collagen gene expression, and even significantly increased type II collagen 
mRNA level over the control (chondrocytes alone) value. After 10 days of incubation, ASU-E 
prevented osteoblast-induced inhibition of aggrecan core protein production. In contrast, 
pretreatment of SC osteoblasts with ASU-E did not significantly modify the expression of MMP-3, 
MMP-13, TIMP-1, TGF-ß1, TGF-ß3, iNOS, or COX-2 gene by chondrocytes [45].  
3. Discussion 
OA is complex disease involving all articular tissues including, meniscus, ligaments, capsule 
cartilage, synovial membrane and subchondral bone. The ideal OA treatment should be active on 
all these tissues because they are all involved in OA physiopathology, signs and symptoms. ASU-E 
is largely used in the treatment of OA around the world. Their effects on symptoms and structural 
changes in OA articular tissues have been well documented. In chondrocytes culture, ASU-E 
increases AGG synthesis and accumulation in the extracellular matrix and inhibits the production 
of pro-inflammatory and pro-catabolic mediators [31–36]. These findings clearly indicate that 
ASU-E may act on different facets of OA chondrocyte metabolism and tends to normalize it. 
Further, ASU-E counteracts the deleterious effect of IL-1 on chondrocytes metabolism. Some of 
these effects have been described to be associated with inhibition of NF-B nuclear translocation 
and increase production of transforming growth factors β1 and β2 in chondrocytes [37]. These data 
give a rationale to explain the structural effects observed in animals [39–43] and humans [23]. In 
animals, this effect is associated with a decrease of iNOS and MMP-13 and with an increase of 
TGF-1/2 levels in synovial fluid. This perfectly corroborates the in vitro study and indicates that 
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after oral intake, ASU-E ingredients or metabolites reach the joint and modulate chondrocyte 
metabolism (Figure 2).  
SC subchondral bone is now recognized to play a major role in OA development and is 
considered as a potential therapeutic target. Subchondral bone sclerosis is suspected to be linked to 
cartilage degradation, not only by modifying the mechanical properties of subchondral bone [49], but 
also by releasing biochemical factors that affect cartilage metabolism [50]. Numerous studies have 
demonstrated that osteoblasts from sclerotic OA subchondral bone are phenotypically different from 
non-sclerotic osteoblasts [51–54]. In example, we have shown that osteoblasts from the sclerotic 
subchondral bone located just below the main cartilage lesion had increased AP and produced more 
IL-6, IL-8, osteopontin, osteocalcin, TGF-1, and type I collagen than osteoblasts from the 
nonsclerotic adjacent area [7]. Since it has been demonstrated that osteoblasts from sclerotic 
subchondral showed an altered phenotype, they constitute a potential therapeutic target for drugs 
used in the treatment of OA. Interestingly, ASU-E inhibits AP and OC synthesis by SC osteoblasts, 2 
markers of new bone formation, and decrease the synthesis of TGF-ß1 by osteoblasts, a growth 
factor postulated to be one of the key regulators of local bone formation [57]. Altogether, these 
observations indicate that ASU-E might be effective on SC subchondral osteoblasts and favor a 
return to bone homeostasis.  
Since the presence of tidemark microcracks that appear early in OA have been identified in OA 
cartilage, it has been suggested that soluble mediators produced by SC osteoblasts may modulate 
chondrocyte metabolism and contribute to cartilage degradation [12]. To verify this hypothesis, we 
developed an original model of culture in which SC osteoblasts and chondrocytes are cultured in the 
same environment, but do not come into contact. The originality of our model lies in the fact that we 
use osteoblasts from the sclerotic subchondral bone, and that OA chondrocytes are cultured in 
alginate beads. A key element in cartilage degradation is an increase in MMP activity. Interestingly, 
we observed that SC osteoblasts induced a strong elevation of MMP-3 and MMP13 synthesis by 
chondrocytes, whereas NSC osteoblasts or normal skin fibroblasts had no effect [45]. This 
observation indicates that osteoblast-induced cartilage degradation is related to its particular SC 
phenotype. In addition to this stimulating effect of SC osteoblasts on MMP synthesis, we also 
observed that AGG content in alginate beads decreased when chondrocytes were co-cultured with SC 
osteoblasts [45] Together, these findings indicate that SC phenotype of osteoblasts induces a marked 
dysregulation of chondrocyte metabolism, characterized by a decrease of matrix component 
synthesis and an increase of MMP production. This imbalance between anabolic and catabolic 
factors could lead to cartilage matrix depletion. ASU-E prevented the inhibitory effect of SC 
osteoblasts on aggrecan synthesis but had no significant effect on MMP, TIMP-1, COX-2, or iNOS 
expressions. This finding demonstrates that ASU-E may protect cartilage by acting at the 
subchondral bone level and suggests a new mechanism of action for this potential  
structure-modifying drug. As all data presented are specific to ASU-E, they are, obviously, neither 
applicable to nor valid for other ASU available on the market. 
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Figure 2. Representation of the effect of ASU-E (A1S2) on OA chondrocytes metabolism. 
4. Conclusion 
In conclusion, ASU-E has a unique composition obtained after unique processes. ASU-E was 
demonstrated to have positive effects on the metabolic changes occurring in three main tissues 
involved in OA pathophysiology. By this way, ASU-E has a global action on the joint and may 
interfere with the three pathological vicious circles binding cartilage, subchondral bone and synovial 
membrane. These experimental observations give a rational to explain the clinical efficacy of ASU-E. 
Some additional investigations would be helpful to better understand the role of ASU-E on synovial 
membrane and meniscus. More particularly, it would be interesting to investigate the effects of  
ASU-E on NF-B and Wnt signaling pathways and on the related production of pro-inflammatory 
cytokines and metalloproteases by synoviocytes.  
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